- The oral Janus kinase 1 (JAK1) inhibitor abrocitinib is associated with clinical improvement compared with placebo in patients with moderate to severe atopic dermatitis, according to results from a phase 2b trial.
Why this matters
- Further therapy options are needed for atopic dermatitis, which is common and associated with substantial patient and caregiver burden.
- Patients receiving abrocitinib had higher rates of improvement (clear/almost clear on Investigator’s Global Assessment scale with improvement ≥2 grades) compared with patients receiving placebo (44.5% for patients receiving 200 mg, 27.8% for patients receiving 100 mg, 6.3% for patients receiving placebo; P<.001 for both abrocitinib doses compared with placebo>
- Abrocitinib 200 mg and abrocitinib 100 mg were associated with greater reductions in the Eczema Area and Severity Index (82.6% and 59.0%, respectively) compared with placebo (35.2%; P<.001 and p=".009," respectively>
- 68.9% of patients experienced adverse events; 3.4% experienced serious treatment-emergent adverse events.
- 267 patients with moderate to severe atopic dermatitis were randomly assigned 1:1:1:1:1 to receive abrocitinib 200, 100, 30, or 10 mg, or placebo for 12 weeks and analysed for efficacy and safety.
- Funding: Pfizer Inc.
- Short trial duration.